

Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO)

AA Brandes^{*1}, A Tosoni², G Cavallo¹, R Bertorelle³, V Gioia⁴, E Franceschi¹, M Biscuola³, V Blatt², L Crinò⁵ and M Ermani⁶

¹Department of Medical Oncology, Bellaria Hospital, 40139 Bologna, Italy; ²Department of Medical Oncology, Istituto Oncologico Veneto-IRCCS, 35128 Padova, Italy; ³Servizio di Immunologia e Diagnostica Molecolare Oncologica – Istituto Oncologico Veneto-IRCCS, 35128 Padova, Italy; ⁴Dipartimento Farmaceutico – Azienda USL of Bologna, 40139 Bologna, Italy; ⁵Department of Medical Oncology Perugia Hospital, 06100 Perugia; ⁶Department of Neurological Sciences, Azienda Ospedale-Università of Padova, 35100 Padova, Italy

The efficacy of temozolomide strongly depends on O⁶-alkylguanine DNA-alkyl transferase (AGAT), which repairs DNA damage caused by the drug itself. Low-dose protracted temozolomide administration can decrease AGAT activity. The main end point of the present study was therefore to test progression-free survival at 6 months (PFS-6) in glioblastoma patients following a prolonged temozolomide schedule. Chemonaïve glioblastoma patients with disease recurrence or progression after surgery and standard radiotherapy were considered eligible. Chemotherapy cycles consisted of temozolomide 75 mg/m²/daily for 21 days every 28 days until disease progression. O⁶-methyl-guanine-DNA-methyl-transferase (MGMT) was determined in 22 patients (66.7%). A total of 33 patients (median age 57 years, range 31–71) with a median KPS of 90 (range 60–100) were accrued. The overall response rate was 9%, and PFS-6 30.3% (95% CI: 18–51%). No correlation was found between the MGMT promoter methylation status of the tumours and the overall response rate, time to progression and survival. In 153 treatment cycles delivered, the most common grade 3/4 event was lymphopenia. The prolonged temozolomide schedule considered in the present study is followed by a high PFS-6 rate; toxicity is acceptable. Further randomised trials should therefore be conducted to confirm the efficacy of this regimen.

British Journal of Cancer (2006) **95**, 1155–1160. doi:10.1038/sj.bjc.6603376 www.bjcancer.com

Published online 3 October 2006

© 2006 Cancer Research UK

Keywords: clinical trials; glioblastoma; MGMT; prolonged temozolomide

Glioblastoma multiforme (GBM), the most aggressive brain tumour in adults despite, advances in diagnosis and treatment made over the past two decades, is still incurable (Brandes, 2003). Every effort should, therefore, be made to develop new approaches that maximise an active drug, such as temozolomide (TMZ), which is the backbone in the treatment of brain tumours. However, the efficacy of this therapy is limited by the presence of intrinsic or acquired resistance mechanisms. Temozolomide exerts its activity by means of DNA methylation at the N⁷ and O⁶ position of guanine and at the O³ position of adenine (Denny *et al*, 1994). Although O⁶-methylguanine accounts for few adducts formed by TMZ, it plays a critical role in the cytotoxicity of the drug. The DNA repair protein, O⁶-alkyl-guanine-DNA-alkyltransferase (AGAT), encoded by the MGMT gene, reverts resistance to TMZ by removing cytotoxic methyl adducts from the O⁶ position of guanine. As AGAT removes methyl adducts from DNA via a suicide mechanism, it has also been suggested that protracted exposure to an

alkylating agent may not only saturate AGAT copies available within cancer cells, but may also inactivate the new molecules while they are being synthesised, thus leading to AGAT 'depletion' and overcoming the inherent resistance of glioma cells.

Tolcher *et al* (2003) showed that mean AGAT activity decreased by 63% in peripheral blood mononuclear cells (PBMC) after 14 days of protracted TMZ treatment, and by 73% after 21 days; these low levels persisted up to day 28. In the present study, AGAT activity in PBMC has been used as a pharmacodynamic surrogate end point for AGAT depletion, although changes in AGAT activity in PBMC may not reflect changes in tumour tissues. A phase I study was performed using this TMZ schedule (3 weeks on/1 week off) in patients with advanced-stage solid malignancies (Denis *et al*, 2000). Dose-limiting toxicity was thrombocytopenia, the maximum-tolerated dose being 100 mg/m². However, as toxicity was detected only after two courses of treatment, no definitive conclusions could be drawn regarding the long-term toxicity of the regimen at this dosage. The aim of the present phase II study was therefore to evaluate the effect of a prolonged TMZ schedule of 75 mg/m²/daily for 21 days every 28 days in relation to progression-free survival at 6 months (PFS-6), response, toxicity and any correlation with MGMT gene promoter methylation status, in patients with recurrent or progressive GBM.

*Correspondence: Dr AA Brandes; E-mail: aa.brandes@yahoo.it

Presented in part at the European Association of Neuro-Oncology, Edinburgh, May 5–8, 2005.

Received 24 July 2006; revised 24 August 2006; accepted 24 August 2006; published online 3 October 2006

MATERIALS AND METHODS

Eligibility

Criteria for eligibility were: histological diagnosis of GBM, age ≥ 18 years, Karnofsky Performance Score (KPS) ≥ 60 , normal baseline counts for neutrophils $\geq 1500/\mu\text{l}$ and platelets $\geq 100\,000/\mu\text{l}$; transaminases and alkaline phosphatase levels ≤ 1.5 times the upper normal limits; bilirubin and creatinine levels ≤ 1.25 times the upper normal limits; previous surgery followed by standard radiotherapy (60 Gy/30 fractions). Unequivocal evidence of disease recurrence or progression at gadolinium-enhanced MRI neuroimaging was also required. Patients accrued had at least one enhancing measurable lesion with a diameter of ≥ 2 cm, evaluated at least 3 months after the end of radiotherapy. Brain imaging, performed within 2 days after surgery, showing residual disease with the above characteristics was mandatory for patients undergoing repeat surgery for recurrence. All patients accrued had been on a stable dose of corticosteroids for at least 2 weeks before initiation of therapy. Patients with childbearing potential were to use effective contraception. Pregnant or breast-feeding patients were ineligible, as were patients who had previously received cytotoxic therapy, presented active infection or other uncontrolled diseases, psychiatric disturbances and/or a history of cancer other than resected nonmelanoma skin cancer or carcinoma *in situ* of the uterine cervix.

Availability of tumour specimens to perform the assessment of *MGMT* promoter methylation status was required for all patients. The study, approved by the Institutional Review Boards of all participating centres, was conducted according to the principles of the Declaration of Helsinki and the rules of Good Clinical Practice. All patients signed a form giving their fully informed consent to participate.

Treatment regimen

All patients were given TMZ 75 mg/m²/daily for 21 days every 28 days. No dose escalation was allowed. Patients fasted for at least 2 h before, and 2 h after, TMZ administration. As continuous daily TMZ can cause lymphopenia, potentially increasing the risk of opportunistic infections, patients received oral trimethoprim-sulphamethoxazole to prevent *Pneumocystis carinii* pneumonia if the lymphocyte count fell to $< 500/\mu\text{l}$ (Kovacs and Masur, 2000). Antiemetic prophylaxis with metoclopramide or a 5-hydroxytryptamine₃ antagonist was also given.

Dose modifications

Patients were closely monitored for toxicity throughout cycles, all adverse events being recorded and graded according to the common toxicity criteria of the National Cancer Institute, version 3.0. (<http://ctep.cancer.gov/forms/CTCAEv3.pdf>).

Haematology was performed weekly, while complete biochemistry was assessed once per cycle, preferably on day 28. Chemotherapy was given if neutrophils were $\geq 1500/\mu\text{l}$, lymphocytes $\geq 500/\mu\text{l}$ and platelets $\geq 100\,000/\mu\text{l}$; otherwise treatment was delayed for a maximum of 3 weeks until adequate recovery. If blood counts analysed throughout 3 weeks were still unsatisfactory, treatment was stopped. In cases of $\geq G3$ haematological toxicity at nadir or reversible $G3$ nonhaematological toxicity (except for nausea/vomiting), TMZ was reduced by 25%. If $G4$ haematological or $G3$ nonhaematological toxicity reappeared notwithstanding dose reductions, or if any type of nonhaematological $G4$ toxicity was observed, chemotherapy was interrupted.

The use of growth factors in order to maintain high blood counts and to administer chemotherapy at fixed intervals was proscribed. Patients were kept at the lowest corticosteroid dosage allowed in relation to their neurological status.

Efficacy measures

Progression-free survival was evaluated from the start of chemotherapy to progression; median survival (MST) was calculated from the start of chemotherapy to death for any reason. In this intent-to-treat study, data on all registered patients were included in the statistical analysis.

PFS, PFS-6 and MST were calculated using the Kaplan–Meier method (Kaplan & Meier, 1958); differences in progression and overall survival (OS) were evaluated by the log-rank test for statistical significance.

Patients were evaluated for response using clinical and neurological examinations (performed monthly before each cycle) and MRI or CT neuroimaging performed every two cycles, or earlier if indicated, according to Macdonald's criteria (Macdonald *et al*, 1990). Neurological status was assessed by considering signs and symptoms possibly correlated with progression, as compared to the previous examination; each variation in daily corticosteroids dosage was recorded.

Responses were confirmed as complete or partial if they were constant at subsequent scans obtained at least 4 weeks apart from each other. An independent central review of CT and MRI scans was made for patients achieving complete (CR) or partial (PR) response or stable disease (SD), evaluated by local investigators. Patients were withdrawn if they had progressive disease, unacceptable toxicity, or retracted their consent.

DNA extraction and methylation-specific polymerase chain reaction

DNA from 10 mm paraffin sections of cerebral lesion was modified by sodium bisulphite, which converts unmethylated cytosine to uracil, according to the procedure of Herman *et al* (1996). Modified DNA was submitted for methylation specific PCR (MSP) by a nested-PCR protocol (Palmisano *et al*, 2000). As the quality of DNA obtained from formalin-fixed paraffin-embedded tumour tissue affects the success rate of MSP, in some cases *MGMT* methylation status was determined by a different nested-MSP approach, with a first pair of primers to obtain smaller amplicons (129 bp), for which forward and reverse primers have been described (Palmisano *et al*, 2000; van Engeland *et al*, 2003).

Statistical analysis

The trial was a phase II study, with PFS-6 percentage as the main end point. According to the Minimax design (Simon, 1989), our study, with its sample size of $n=33$, had a 5% probability of rejecting (α) the hypothesis of a PFS-6 10% (P_0) and a 90% probability of accepting ($1-\beta$) the hypothesis of a PFS-6 of 30% (P_1). If two, or fewer of the first 22 patients were progression free at 6 months, PFS-6 would be considered $< 10\%$ and the study terminated. Otherwise, the study would be completed, the accrual target being 33 patients. If six or fewer of the 33 patients were progression-free at 6 months, then no further investigation of the treatment regimen was considered warranted. PFS, PFS-6 and OS were calculated using the Kaplan–Meier method (Kaplan and Meier, 1958), and differences in progression and survival in relation to prognostic factors were evaluated with the log-rank test. Student's *T* and the Mann–Whitney *U*-tests were used to analyse normally and non-normally distributed variables between groups. All calculations were performed using S-PLUS software (MathSoft Inc., Seattle, WA, USA).

RESULTS

Patient characteristics

From November 2003 to September 2005, 33 patients (13 females; median age 57, range 31–71 years; median KPS 90, range 60–100)

were enrolled; their characteristics are reported in Table 1. All patients were evaluated for drug activity and toxicity.

Methylation specific PCR analysis

Methylation specific PCR (MSP) analysis was performed in all 33 patients enrolled in the trial. However, results were evaluable only in 22 patients, with an MSP success rate of 66%; this finding is comparable to those reported by other authors (Hegi *et al*, 2005).

Among 22 patients for whom MSP was evaluable, 10 (45.5%) presented *MGMT* promoter methylated and 12 unmethylated (54.5%) status. No differences were found between patients with *MGMT* promoter methylated and those with unmethylated status for age ($P=0.16$), gender ($P=0.39$), performance status (PS) ($P=0.72$), time-intervals between surgery and start of chemotherapy ($P=0.21$), or between the end of radiotherapy and start of chemotherapy ($P=0.15$). All patients had undergone one surgical procedure and full-dose radiotherapy, completed at least 3 months previously, but none had been given cytotoxic or cytostatic drugs.

Progression-free survival

All patients were followed-up to disease progression. The percentage of patients without progression at 6 months (PFS-6) was 30.3% (95%CI: 18–51%). Overall, the median PFS was 16.1 weeks (95%CI: 12.4–27.3), 15.6 weeks (CI: 11–NA) and 11.9 weeks (CI: 10.3–31.6) in patients with *MGMT* promoter methylated status and in patients with unmethylated *MGMT* promoter status, respectively. No significant differences were found between PFS, evaluated using the log-rank test, in relation to age ($P=0.42$), KPS ($P=0.77$), type of surgery ($P=0.58$) and *MGMT* promoter methylated or unmethylated status ($P=0.86$).

Response

Among the 33 evaluable patients, one CR (3%) and two PR (6%) were obtained, with an overall response rate of 9% (CI: 0–18.8%).

Table 1 Characteristics of patients

	No. of patients (%)
<i>Gender</i>	
Female	13 (39)
Male	20 (61)
<i>Age (years)</i>	
Median	57
Range	31–71
<i>KPS</i>	
Median	90
Range	60–100
<i>Extent of resection</i>	
Gross total resection	13 (39)
Partial resection or biopsy	20 (61)
<i>Previous treatment</i>	
Primary resection	33 (100)
Radiotherapy	33 (100)
Chemotherapy	0
Repeat surgery for recurrence	1
<i>Cycles of temozolomide</i>	
≤3	18
4–6	7
7–9	6
>10	2

Seventeen patients had SD (51%; CI: 34.4–68.6%). All radiological responses were confirmed by an independent centralised review, and stable or decreased steroid dosage was confirmed in all patients on recording responses, which had a median duration of 30.4 weeks, the median duration of disease stabilisation being 25.6 weeks. No correlations were found between response to therapy and age ($P=0.32$), KPS ($P=0.96$), time-interval between surgery and end of radiotherapy ($P=0.38$), *MGMT* promoter methylated or unmethylated status ($P=0.63$) in responders (CR + PR) and SD patients *vs* PD patients.

Overall survival

Median survival as from the start of chemotherapy was 40 weeks (CI: 31–63), although this outcome may have been influenced by second-line treatments, 12 patients being treated with nitrosourea-based regimens, 3 with carboplatin and etoposide, 3 with new experimental drugs, and 15 with no other treatments. In all, 73% (CI: 59–90%) and 38% (CI: 24–59%) of the patients were alive at 6 and 12 months, respectively. Median survival and percentage of patients alive at 1 year in cases with methylated *MGMT* promoter status were 48.2 weeks (CI: 29–NA) and 50% (95% CI: 27–93%), respectively; in patients with unmethylated *MGMT* promoter status, these figures were 34.7 weeks (95% CI: 30–64.1) and 21.4% (CI: 8–58%), respectively. Only KPS (<90 *vs* ≥90) was related to survival ($P=0.05$) (Figure 1).

Toxicity

A total of 153 treatment cycles were given to 33 patients, the median number of cycles per patient was three (range 1–15). The most common adverse event was lymphopenia (Table 2). As the cycles were delivered, a clear trend toward an increase in lymphopenia was observed, being present in 30% of patients during the first three cycles, and in 55% of the patients in the subsequent cycles.

Although none of the patients had pneumocystis carinii pneumonia, five (13.6%) had grade 1–3 infections (one herpes zoster, one urinary infection and three upper respiratory tract infection) associated with lymphopenia grade 1 (one patient), grade 2 (two patients) and grade 3 (two patients). The most commonly found nonhaematological symptoms and signs of toxicity were constipation and grade 1–3 asymptomatic transaminase increase, observed in seven patients (21.2%). Eight cycles (5.2%) were delayed for a median time of 1 week (recovery




Figure 1 Thin line PFS. Thick line: OS.

Table 2 Toxicity per patient

	Grade 1 no. of patients (%)	Grade 2 no. of patients (%)	Grade 3 no. of patients (%)	Grade 4 no. of patients (%)
Neutropenia	1 (3)	2 (6)	2 (6)	2 (6)
Lymphopenia	1 (3)	6 (18.2)	8 (24.2)	0
Thrombocytopenia	1 (3)	0	0	1 (3)
Anemia	5 (15.2)	1 (3)	1 (3)	0
Nausea	0	2 (6)	1 (3)	0
Constipation	4 (12.1)	4 (12.1)	1 (3)	0
Increased transaminase	5 (15.2)	1 (3)	1 (3)	0
Infection with lymphopenia	1 (3)	3 (9.1)	1 (3)	0

after 1–7 weeks) due to grade 3 lymphopenia (25%), grade 2 infections (25%) and grade 4 neutropenia (25%).

The most common reason for drug discontinuation was disease progression, which occurred in 93.9% of patients. One patient died of pulmonary embolism, probably unrelated to TMZ administration; one discontinued treatment due to prolonged (7 weeks) grade 4 pancytopenia.

Based on the supposition that *MGMT*, a potent drug resistance gene, might be implicated in the protection of haematopoietic stem cells during chemotherapy (Gerson, 2004) a search was made for a correlation between *MGMT* promoter status and toxicity. However, *MGMT* promoter methylation status was determined on tumour samples, and not in blood, thus indicating only an indirect correlation between *MGMT* and toxicity. Grade 3–4 leukopenia was observed in three patients with methylated *MGMT* promoter and in one patient with unmethylated *MGMT* promoter, lymphopenia grade 3 was observed in four patients with methylated *MGMT* promoter, and in one with unmethylated *MGMT* promoter.

DISCUSSION

In GBM patients with first recurrence, TMZ is active at a standard single daily dose of 150–200 mg/m², administered for five days every 4 weeks. In the three available studies investigating this regimen in this setting, PFS-6 was 21% (Yung *et al*, 2000) (CI:13–29%), 18% (Brada *et al*, 2001) (CI:11–24%), and 24% (Brandes *et al*, 2002) (CI:14–42%). As the antitumour activity of TMZ depends on the level of AGAT within tumour cells, several trials have aimed to deplete AGAT via a continuous dosing schedule (Tolcher *et al*, 2003). In their phase II study with continuous TMZ administration at a dosage of 75 mg/m²/day over a 6-week period with 4 weeks' rest, in 28 pretreated GBM patients, Khan *et al* achieved a PFS-6 of 19%, a median PFS 2.3 months and zero responses. This schedule thus allowed a higher dose intensity (1260 mg/m²) over 4 weeks than the standard schedule (1000 mg/m²) with good tolerability, although the results did not support its use in patients with recurrent GBM. Wick *et al* (2004) treated 21 GBM patients with a different 28-day period continuous schedule (TMZ at 150 mg/m² delivered for 1-week on/1-week off) with a drug intensity of 2100 mg/m² and AGAT (Tolcher *et al*, 2003) was depleted: a PFS-6 of 48% was obtained (43% patients were pretreated with 1–2 chemotherapy regimens) with modest toxicity. However, on using the same regimen, Chinot *et al* (2005) obtained a PFS-6 of only 21% in 29 inoperable previously untreated GBM patients.

We treated recurrent chemo-naïve GBM patients with a continuous TMZ schedule for 21 days every 28 days, and a PFS-6 of 30.3% was obtained. Our findings may have been influenced by several factors: chemotherapy administered at relatively low doses while following a frequent metronomic schedule may have optimised the antiangiogenic effect of cytotoxic agents, providing

better results than an intensified weekly schedule (Kurzen *et al*, 2003). Moreover, a high-dose intensity (1575 mg/m²) was achieved and AGAT depletion was more prolonged than in a weekly schedule, in which recovery of AGAT activity begins immediately after 7 days (Tolcher *et al*, 2003).

The results reported in studies on *MGMT* gene promoter status are controversial. It has been maintained that *MGMT* promoter methylation assessed by MSP is associated with a longer survival in GBM patients treated with radiotherapy and TMZ (18.2 vs 12.2 months, $P < 0.001$) (Hegi *et al*, 2005). However, Paz *et al* (2004) reported that *MGMT* promoter methylation was correlated with response to standard TMZ, but not with OS. Findings made using alternative methods (immunohistochemistry or activity tests) are contradictory, some confirming (Friedman *et al*, 1998) and others denying (Middleton *et al*, 1998) a relationship with time to progression or response to TMZ.

To our knowledge, ours is the first trial to study correlations between *MGMT* promoter methylation status, assessed by MSP, and treatment outcome with a continuous TMZ schedule. Findings for/MSP were available in 22 (66.7%) of the 33 patients enrolled in the study; this percentage is similar to those reported (59–67%) in MSP studies made by other authors (Hegi *et al*, 2004; Hegi *et al*, 2005). In our study, an overall median PFS of about 4 months and a PFS-6 of 30.3% were obtained: these results appear superior to those obtained with the standard TMZ schedule. In 22 patients for whom *MGMT* promoter status was available, no significant difference was found between *MGMT* promoter methylated or unmethylated patients for median PFS and PFS-6 (15.6 weeks and 20% vs 11.9 weeks and 21.4%). This suggests that AGAT depletion achieved with protracted TMZ increases the sensitivity of unmethylated tumours to TMZ, leading to an increase in PFS and OS which would have been less than that obtained by us if these patients had been treated with the traditional TMZ schedule. However, this observation, based on a small number of patients, should be demonstrated by findings from prospective studies with patients stratified according to methylation status, as in the ongoing phase III RTOG/EORTC study.

The standard TMZ schedule (Brada *et al*, 2001; Yung *et al*, 2000) incurs higher grade 3/4 thrombocytopenia (7–10% vs 3) and lower grade 3/4 neutropenia (4–4.5% vs 12) rates than our 3-week on/1-week off schedule. Cumulative lymphopenia was observed in 45.4% of our patients, this outcome being comparable to those reported by other authors following other protracted schedules (Brock *et al*, 1998; Khan *et al*, 2002; Su *et al*, 2004; Wick and Weller, 2005). This high incidence of lymphopenia may have been due in part to the concomitant administration of steroids: 75% of patients received both steroids and continuous TMZ. The standard TMZ schedule rarely leads to lymphopenia, no such cases being reported in 250 GBM patients treated in phase II–III trials (Yung *et al*, 2000; Brada *et al*, 2001).

Although the number of severe haematologic events observed by us may be of limited statistical power, we observed an association

between grade 3 lymphopenia, grade 4 haematological toxicity and *MGMT* status. Based on experimental evidence indicating low AGAT activity in bone marrow CD34 cells (Gerson *et al*, 1996), it may be suggested that haematological progenitors are especially sensitive to strategies that inactivate AGAT: when O⁶ benzylguanine, an AGAT specific inhibitor, is added to BCNU, haematological toxicity increases (Friedman *et al*, 2000). A correlation between AGAT activity in PBMC and haematological toxicity has been demonstrated by Tolcher *et al* (2003) in patients treated with a prolonged schedule. However, in our study *MGMT* promoter methylation status was assessed only on tumour samples, and *MGMT* promoter methylation may vary among different tissues. Based on these considerations it would be interesting to conduct a prospective trial studying *MGMT* expression in blood and tumour samples in order to understand the activity of temozolomide and its toxicity profile as this would be conducive to personalising drug delivery.

In June 2005, TMZ concomitant with radiotherapy followed by six cycles of maintenance chemotherapy became standard therapy worldwide (Stupp *et al*, 2005). The present study will therefore probably be the last classic phase II trial to be performed using an alternative TMZ schedule as first-line chemotherapy in chemonaïve and recurrent patients after standard radiotherapy. The findings made indicate that a phase III trial on a larger series should be launched in order to evaluate whether new chemo-

therapy regimens combining dose-intensity concepts with the manipulation of chemoresistance may yield a good risk/benefit/cost ratio in glioblastoma patients.

ACKNOWLEDGEMENTS

The authors are grateful to all the following institutions and investigators for providing clinical information on, and specimens of patients enrolled in the study. Department of Pathology (V Eusebi, A Pession), Bellaria Hospital, Bologna, Italy; Departments of Neurosurgery (AM Cremonini), Medical Oncology (M Faedi), and Pathology (M Cerasoli), Cesena Hospital, Cesena, Italy; Departments of Medical Oncology (B Urbini) and Pathology (L Cavazzini) Ferrara Hospital, Ferrara, Italy; Departments of Pathology (V Ninno, M Rugge, M Gardiman) and Neurosurgery (A Rotilio, R Mottaran), Padova University Hospital, Italy; Departments of Pathology (E D'Amore, D Danieli) and Medical Oncology (B Coria), Vicenza Hospital, Vicenza, Italy; Departments of Neurosurgery (S Turazzi, R Gambin, A Talacchi) and Pathology (C Ghimenton), Verona University Hospital, Verona, Italy; Department of Pathology (P Iuzzolino), Belluno Hospital, Belluno, Italy.

The authors also express their gratitude to Azienda-Ospedale-Università di Padova, Italy for providing funds for the research.

REFERENCES

- Brada M, Hoang-Xuan K, Rampling R, Dietrich PY, Dirix LY, Macdonald D, Heimans JJ, Zonnenberg BA, Bravo-Marques JM, Henriksson R, Stupp R, Yue N, Bruner J, Dugan M, Rao S, Zaknoen S (2001) Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. *Ann Oncol* **12**: 259–266
- Brandes AA (2003) State-of-the-art treatment of high-grade brain tumors. *Semin Oncol* **30**: 4–9
- Brandes AA, Ermani M, Basso U, Paris MK, Lumachi F, Berti F, Amista P, Gardiman M, Iuzzolino P, Turazzi S, Monfardini S (2002) Temozolomide in patients with glioblastoma at second relapse after first line nitrosourea-procarbazine failure: a phase II study. *Oncology* **63**: 38–41
- Brock CS, Newlands ES, Wedge SR, Bower M, Evans H, Colquhoun I, Roddie M, Glaser M, Brampton MH, Rustin GJ (1998) Phase I trial of temozolomide using an extended continuous oral schedule. *Cancer Res* **58**: 4363–4367
- Chinot O, Barrié M, Cournède A, Dufor H, Figarella-Branger D, Braguer D, Peragut JC, Grisoli F (2005) Phase II study of temozolomide (TMZ) administered on a 7 days on-7days off regimen as primary treatment before radiotherapy (RT) in inoperable newly diagnosed glioblastoma multiforme (GBM). *J Clin Oncol, ASCO Annual Meeting Proc* **23**(16S, Part I of II, June 1 Suppl): 1523
- Denis L, Tolcher A, Figueroa J, Dregler R, Geyer C, Eckhardt S, Cutler D, Reyderman L, Von Hoff D, Rowinsky E (2000) Protracted daily administration of temozolomide is feasible: a phase I and pharmacokinetic – Pharmacodynamic Study. *ASCO Proc* **19**(abs. n. 786)
- Denny BJ, Wheelhouse RT, Stevens MF, Tsang LL, Slack JA (1994) NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. *Biochemistry* **33**: 9045–9051
- Friedman HS, McLendon RE, Kerby T, Dugan M, Bigner SH, Henry AJ, Ashley DM, Krischer J, Lovell S, Rasheed K, Marchev F, Seman AJ, Cokgor I, Rich J, Stewart E, Colvin OM, Provenzale JM, Bigner DD, Haglund MM, Friedman AH, Modrich PL (1998) DNA mismatch repair and O⁶-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. *J Clin Oncol* **16**: 3851–3857
- Friedman HS, Pluda J, Quinn JA, Ewesuedo RB, Long L, Friedman AH, Cokgor I, Colvin OM, Haglund MM, Ashley DM, Rich JN, Sampson J, Pegg AE, Moschel RC, McLendon RE, Provenzale JM, Stewart ES, Tourt-Uhlig S, Garcia-Turner AM, Herndon II JE, Bigner DD, Dolan ME (2000) Phase I trial of carmustine plus O⁶-benzylguanine for patients with recurrent or progressive malignant glioma. *J Clin Oncol* **18**: 3522–3528
- Gerson SL (2004) *MGMT*: its role in cancer aetiology and cancer therapeutics. *Nat Rev Cancer* **4**: 296–307
- Gerson SL, Phillips W, Kastan M, Dumenco LL, Donovan C (1996) Human CD34+ hematopoietic progenitors have low, cytokine-unresponsive O⁶-alkylguanine-DNA alkyltransferase and are sensitive to O⁶-benzylguanine plus BCNU. *Blood* **88**: 1649–1655
- Hegi ME, Diserens AC, Godard S, Dietrich PY, Regli L, Ostermann S, Otten P, Van Melle G, de Tribolet N, Stupp R (2004) Clinical trial substantiates the predictive value of O⁶-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. *Clin Cancer Res* **10**: 1871–1874
- Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) *MGMT* gene silencing and benefit from temozolomide in glioblastoma. *N Engl J Med* **352**: 997–1003
- Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB (1996) Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. *Proc Natl Acad Sci USA* **93**: 9821–9826
- Kaplan E, Meier P (1958) Non parametric estimation for incomplete observation. *J Am Stat Assoc* **53**: 457–481
- Khan RB, Raizer JJ, Malkin MG, Bazylewicz KA, Abrey LE (2002) A phase II study of extended low-dose temozolomide in recurrent malignant gliomas. *Neuro-oncol* **4**: 39–43
- Kovacs JA, Masur H (2000) Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection. *N Engl J Med* **342**: 1416–1429
- Kurzen H, Schmitt S, Naher H, Mohler T (2003) Inhibition of angiogenesis by non-toxic doses of temozolomide. *Anticancer Drugs* **14**: 515–522
- Macdonald DR, Cascino TL, Schold Jr SC, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. *J Clin Oncol* **8**: 1277–1280
- Middleton MR, Lunn JM, Morris C, Rustin G, Wedge SR, Brampton MH, Lind MJ, Lee SM, Newell DR, Bleehen NM, Newlands ES, Calvert AH, Margison GP, Thatcher N (1998) O⁶-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma. *Br J Cancer* **78**: 1199–1202
- Palmisano WA, Divine KK, Saccomanno G, Gilliland FD, Baylin SB, Herman JG, Belinsky SA (2000) Predicting lung cancer by detecting aberrant promoter methylation in sputum. *Cancer Res* **60**: 5954–5958
- Paz MF, Yaya-Tur R, Rojas-Marcos I, Reyes G, Pollan M, Aguirre-Cruz L, Garcia-Lopez JL, Piquer J, Safont MJ, Balana C, Sanchez-Céspedes M,

- Garcia-Villanueva M, Arribas L, Esteller M (2004) CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. *Clin Cancer Res* **10**: 4933–4938
- Simon R (1989) Designs for efficient clinical trials. *Oncology (Huntingt)* **3**: 43–49; discussion 51–53
- Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirmanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. *N Engl J Med* **352**: 987–996
- Su YB, Sohn S, Krown SE, Livingston PO, Wolchok JD, Quinn C, Williams L, Foster T, Sepkowitz KA, Chapman PB (2004) Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. *J Clin Oncol* **22**: 610–616
- Tolcher AW, Gerson SL, Denis L, Geyer C, Hammond LA, Patnaik A, Goetz AD, Schwartz G, Edwards T, Reyderman L, Statkevich P, Cutler DL, Rowinsky EK (2003) Marked inactivation of O⁶-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. *Br J Cancer* **88**: 1004–1011
- van Engeland M, Weijenberg MP, Roemen GM, Brink M, de Bruine AP, Goldbohm RA, van den Brandt PA, Baylin SB, de Goeij AF, Herman JG (2003) Effects of dietary folate and alcohol intake on promoter methylation in sporadic colorectal cancer: the Netherlands cohort study on diet and cancer. *Cancer Res* **63**: 3133–3137
- Wick W, Steinbach JP, Kuker WM, Dichgans J, Bamberg M, Weller M (2004) One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma. *Neurology* **62**: 2113–2115
- Wick W, Weller M (2005) How lymphotoxic is dose-intensified temozolomide? The glioblastoma experience. *J Clin Oncol* **23**: 4235–4236; author reply 4236
- Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, Brada M, Spence A, Hohl RJ, Shapiro W, Glantz M, Greenberg H, Selker RG, Vick NA, Rampling R, Friedman H, Phillips P, Bruner J, Yue N, Osoba D, Zaknoen S, Levin VA (2000) A phase II study of temozolomide vs procarbazine in patients with glioblastoma multiforme at first relapse. *Br J Cancer* **83**: 588–593